SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is trending as escalating conflict with Iran and reported strikes on oil infrastructure fuel fears of global supply disruption, with the community sharply divided on whether crude prices will soar or face an imminent "rug pull" amid geopolitical tensions.

"What's Updog?" is a Community Led token.

UpDog

UPDOG CRYPTO is actively trending with its community celebrating its notable longevity as a Solana-based meme coin, fostering engagement through playful "Whats UpDog?" interactions and calls to "stack those bags." The project emphasizes its robust foundation with locked liquidity and a presence on Jupiter's Strict List, fueling optimistic discussions for future growth.

Trump For President

TRUMP CRYPTO is trending due to its substantial price decline, igniting heated community debate where many critics label it a "scam" or "con job" tied to broader political controversies surrounding Donald Trump. A segment of supporters, however, maintains a bullish stance, dismissing negative sentiment as politically motivated.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is currently trending with strong community conviction, driven by its unique 'permissionless brand' model encompassing numerous real-world initiatives like Kendu Spice and Kendu Energy, alongside its recent verification on Swappy across ETH and BASE networks, prompting calls for consistent DCA and long-term hodling.

ProShares Trust - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

Heightened Middle East geopolitical tensions, particularly concerning Iran and the Strait of Hormuz, are fueling intense interest in ProShares Ultra Bloomberg Crude Oil (UCO), as the community widely discusses potential crude oil supply disruptions and the prospect of significant price surges amidst cautious sentiment.

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

Solid Biosciences Inc

Solid Biosciences is actively discussed following a recent oversubscribed private financing that significantly strengthens its balance sheet and extends its operational runway, coupled with positive regulatory updates across its gene therapy pipeline. The community highlights the company's de-risked financial position and promising clinical data, drawing strong institutional interest, while some maintain caution regarding past dilution and the demanding regulatory environment.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending after its Q4 earnings report highlighted wider-than-expected losses and substantial cash burn, sparking a heated debate among investors. Bulls are focused on the company's achievement of 100% FAA Means of Compliance and emerging defense partnerships, while bears remain highly critical of spending, dilution concerns, and the timeline for piloted eVTOL operations.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SLS is trending on intense speculation surrounding the imminent Phase 3 REGAL trial results for its potential "curative" AML treatment, GPS, amplified by recent strong commentary from its CEO on the drug's adaptive immunotherapy platform. Investors are keenly watching for a potential Big Pharma acquisition and a major short squeeze, as discussions at a key industry summit further fuel optimism.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd is trending as escalating Middle East tensions, marked by attacks on oil infrastructure and disruptions to shipping routes, drive crude oil prices significantly higher. The community is buzzing about a potential massive short squeeze in this low-float oil stock, reminiscent of its past explosive moves during similar geopolitical events.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is rallying sharply after a Q4 earnings beat and optimistic Q1 guidance, fueling widespread analyst upgrades and community speculation of a significant short squeeze. The market is actively discussing whether this marks a critical turnaround for the solar sector, driven by demand for ENPH's advanced battery storage and microinverter solutions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Needham raised its 2026 e-commerce revenue forecast from $1.05 billion to $1.45 billion.</li><li>The firm noted that AppLovin’s share price has recently retreated from its peak a month ago, presenting a potential buying opportunity for investors.</li><li>Needham also highlighted the potential for upside beyond current projections, suggesting that AppLovin could follow a growth trajectory similar to TikTok's.</li></ul>AppLovin (APP) has received a bullish upgrade from Needham, which raised its rating to ‘Buy’ from ‘Hold’ and set a $700 price target, reflecting renewed confidence in the company’s e-commerce growth potential for 2026.&nbsp;The price target implies a potential 33% upside from the company’s Friday closing price.&nbsp;<h2 class="st-heading-2">Revenue Growth Outlook</h2>The move comes after Needham observed strong performance in AppLovin’s e-commerce segment, particularly driven by its self-service advertising platform. The firm raised its 2026 e-commerce revenue forecast from $1.05 billion to $1.45 billion, citing increased advertiser adoption and higher spending that could offset the usual seasonal dip in the first quarter.&nbsp;<a href="https://stocktwits.com/symbol/APP">AppLovin stock</a> traded over 5% higher on Monday morning. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory while message volume changed to ‘high’ from ‘extremely high’ levels in 24 hours.&nbsp;The firm noted that AppLovin’s share price has recently retreated from its peak a month ago, presenting a potential buying opportunity for investors. Needham also highlighted the potential for upside beyond current projections, suggesting that AppLovin could follow a growth trajectory similar to TikTok in the e-commerce and digital advertising spaces.<h2 class="st-heading-2">Fourth-Quarter Earnings&nbsp;</h2>The company is scheduled to report its fourth-quarter earnings on February 11 and expects revenue in the range of $1.57 billion and $1.6 billion. Analysts see a revenue of $1.61 billion and earnings per share of $2.95.&nbsp;Founded in 2012, AppLovin specializes in mobile advertising technology and software solutions for app developers. Its platform connects advertisers with consumers through programmatic campaigns while enabling app publishers to monetize effectively.&nbsp;However, last week, Capitalwatch released a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.capitalwatch.com/">report</a> accusing AppLovin’s main shareholders, Hao Tang and Ling Tang, of using the company to move large amounts of illegal money. The report claimed that criminal groups paid AppLovin huge advertising fees through its AXON and Array systems to launder illicit funds.&nbsp;APP stock has gained over 58% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/inmd-stock-jumped-today-what-is-powering-the-rally/cmy7tBNR4h4">INMD Stock Jumped Nearly 13% Today – What’s Powering The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the AppLovin Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

AppLovin Stock Gets A Needham Upgrade – Why Does The Firm See A 33% Upside Potential For The Stock?

Needham said it observed strong performance in AppLovin’s e-commerce segment, particularly driven by its self-service advertising platform.

Equity

Needham said it observed strong performance in AppLovin’s e-commerce segment, particularly driven by its self-service advertising platform.


<ul class="summary-bullets"><li>It is now unclear when the company would apply for approval of the gene therapy, it said.</li><li>uniQure, however, added that it intends to communicate with the FDA to determine a path forward toward approval of the therapy.&nbsp;</li><li>uniQure CEO termed the meeting outcome “unexpected.” &nbsp;</li></ul>uniQure N.V. (QURE) no longer believes that the U.S. Food and Drug Administration considers data from an early-to mid-stage trial of its investigational gene therapy for Huntington’s disease sufficient for approval, the company said on Monday.The company recently met with the agency, and although the minutes of the meeting have not been received, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/03/3179114/0/en/uniQure-Provides-Regulatory-Update-on-AMT-130-for-Huntington-s-Disease.html">believes</a> that the FDA no longer considers the data from the AMT-130 trial adequate to provide primary evidence in support of an application for approval.As a result, it is now unclear when the company would apply for approval of the gene therapy, it said. uniQure, however, added that it intends to communicate with the FDA to determine a path forward toward approval of the therapy.<h2 class="st-heading-2">CEO Reacts</h2>uniQure CEO termed the meeting outcome “unexpected.”“We are surprised by the FDA’s feedback at the recent pre-BLA meeting, which is a drastic change from the guidance the FDA provided in November 2024 that data from the ongoing Phase I/II studies, compared to a natural history external control, may serve as the primary basis for a BLA submission under the Accelerated Approval pathway,” CEO Matt Kapusta said.The company also stated that it intends to engage in further communications with other regulatory agencies while working with the FDA.<h2 class="st-heading-2">Expert Take</h2>Stifel analyst Annabel Samimy said that the news regarding the FDA's reversal on the approvability of uniQure's AMT-130 based on early to mid-stage trial data on the surface injects another layer of uncertainty into the workings of the FDA and their receptivity to gene therapy, more specifically.The analyst, however, does not expect this to impact Regenxbio’s (RGNX) rare disease programs. Meanwhile, Raymond James added that it does not expect the meeting outcome to impact Biohaven (BHVN) either.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>QURE stock traded 55% lower at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/QURE">QURE stock</a> fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.QURE stock is up 72% this year and approximately 445% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tg-therapeutics-stock-soars-after-company-ups-guidance-for-multiple-sclerosis-drug/cL2NEPSR3zl">TG Therapeutics Stock Soars After Company Ups Guidance For Multiple Sclerosis Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the uniQure logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

uniQure Stock Tumbled 55% Today: What’s The FDA Angle?

The company recently met with the FDA and believes that the agency no longer considers the data from an early-to-mid-stage trial of its investigational gene therapy sufficient for approval.

Current Price	$19.69
Prev Close	$20.15
Open	$19.74
Dividend Yield	N/A
50-Day Moving Average	$21.22
Beta	N/A
Avg. Volume	30,160.45
PE Ratio	N/A

52-Week High	$23.36
52-Week Low	$13.56
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

FRTY
Alger Funds - Alger Mid Cap 40 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest FRTY News

FRTYAlger Funds - Alger Mid Cap 40 ETF